TCGA-BT-A42E-01A-11R-A23W-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 36.39947438
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.590
- INTERFERON_ALPHA_RESPONSE+0.590
- TNFA_SIGNALING_VIA_NFKB+0.580
- INTERFERON_GAMMA_RESPONSE+0.550
- INFLAMMATORY_RESPONSE+0.520
- IL6_JAK_STAT3_SIGNALING+0.480
- KRAS_SIGNALING_DN+0.370
- COMPLEMENT+0.320
- G2M_CHECKPOINT+0.320
- E2F_TARGETS+0.290
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.430
- ADIPOGENESIS-0.330
- PEROXISOME-0.320
- DNA_REPAIR-0.260
- BILE_ACID_METABOLISM-0.250
- FATTY_ACID_METABOLISM-0.250
- PROTEIN_SECRETION-0.250
- MITOTIC_SPINDLE-0.230
- PI3K_AKT_MTOR_SIGNALING-0.220
- TGF_BETA_SIGNALING-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516078 | — | — | 0.880 |
| 2 | R317 | — | — | 0.870 |
| 3 | TCGA-E9-A1ND-01A-11R-A144-07 | — | E | 0.864 |
| 4 | BS_15ETQ0E4 | ATRT | — | 0.863 |
| 5 | BS_PGHK1JRW | ATRT | — | 0.857 |
| 6 | R252 | — | — | 0.856 |
| 7 | MNG943 | — | — | 0.839 |
| 8 | MBCProject_7544_T1_RNA | — | D | 0.832 |
| 9 | TCGA-21-1070-01A-01R-0692-07 | — | cohortSQ1 | 0.826 |
| 10 | s0122149 | — | — | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.590 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.590 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.580 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.550 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.520 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.370 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| APOPTOSIS | 0.230 | Idelalisib | — uncovered |
| HYPOXIA | 0.230 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |